The Liver Meeting 2024 - Debrief Sessions - Spanish-Heptocellular Debrief Session

Video Transcription

Video Summary

Dr. Nihar Parikh from the University of Michigan provided a comprehensive overview of recent advancements in hepatocellular carcinoma (HCC) research. Key topics included risk prediction, surveillance, prognosis, and treatment. For risk prediction, new genetic architectures were identified to help stratify risks for HCC, highlighting genetic risk scores that predict disease progression. Another focus was on non-cirrhotic HCC, with research revealing TERT polymorphisms as significant drivers. In surveillance, studies suggested lowering AFP thresholds for improved sensitivity in non-viral liver disease cases. Prognostic models for HCC were developed to better predict survival without relying solely on subjective criteria. Treatment insights included studies on STRIDE regimen's effectiveness in patients with advanced liver disease and a LEAP012 study that combined Linvatinib, Pembrolizumab, and TACE, showing improved progression-free survival. However, concerns about adverse events, particularly in therapeutic combinations, were noted. These advancements aim to enhance HCC management through better prediction, surveillance, and treatment strategies.

Keywords

hepatocellular carcinoma

risk prediction

genetic architectures

prognostic models

treatment strategies